Senhwa Biosciences focuses on cancer immunotherapy and has been building an AI-powered discovery platform to complement its clinical programs. The company collaborates with emerging AI-native firms and leverages advanced methods — including cell-to-sentence modeling — to probe tumor biology and identify combination therapy opportunities. Its AI-enabled validation has shown promising immunomodulatory potential for lead candidates in specific tumor microenvironments, supporting a ‘‘cold-to-hot tumor’’ strategy to enhance immune responses. Senhwa plans to use the newly secured strategic capital to advance its clinical pipeline, deepen AI integration across discovery and validation, and pursue global expansion and commercialization opportunities. No revenue, user metrics, founding year, or location details were provided in the articles.

Total raised

$17M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2013